3 years ago

The Canadian drug giant Valeant Pharmaceuticals Intl Inc. (NYSE:VRX) announced results of its fiscal fourth quarter as its revenue plunged 13% during the period, affected by the performance of the stomach-drug business it attempted to sell late last year as well as falling medicines prices.

The company's shares has been badly hit by concerns about drug-price rise, accounting problems and a clash with potential debt default.

Valeant Pharmaceuticals Intl Inc. (NYSE:VRX) ‘s earnings have beaten analysts' predictions at a time when investors are watching for signs of what kind of prosperity Valeant can offer as it distance itself from large takeovers and large price surges for its drugs.

However some analysts have shown apprehension about Valeant's debt burden and have questioned the potency of its drug pipeline.

Meanwhile for the full-year, Valeant said it sees revenue in a range of $8.9 billion to $9.1 billion in contrast with the analysts' predictions of $8.96 billion.

Furthermore Company's Chairman and Chief Executive Joseph Papa said in a statement that Valeant is showing heartening rise in average sales prices. Still, revenue in the firm's Branded Rx segment plunged 17%, hurt by stomach-drug business Salix Pharmaceuticals as well as lower pricing because of managed-care rebates and increased generic competition.

It was reported late last year that Valeant's discussions to sell Salix to Takeda Pharmaceutical Co. for around $10 billion had not reached any conclusion. Valeant is well on track with plans to build the sales force for Salix's crown jewel, the irritable-bowel drug Xifaxan.

Overall in the previous quarter Valeant Pharmaceuticals Intl Inc(NYSE:VRX) revealed a net loss of $515 million, or $1.47 a share, in contrast with a loss of $385 billion, or $1.12 a share, year over year. Exclusive of certain items, the company had earnings of $1.26 a share, in contrast with $1.55 the year before. Analysts in the mean time were expecting earnings of  $1.19 a share.

People Mentioned

Justin Sun

Founder of TRON (TRX)

Coins Mentioned

Justin Sun

Founder of TRON (TRX)

Companies Mentioned

Justin Sun

Founder of TRON (TRX)

Justin Sun

Founder of TRON (TRX)

+ 1.45%
Icon
Nitrogen Sports

Lorem Ipsum is simply dummy text of the printing and typesetting indu...

Icon
SportBet.io

Lorem Ipsum is simply dummy text of the printing and typesetting indu...

Icon
7bitcasino

Lorem Ipsum is simply dummy text of the printing and typesetting indu...

Icon
FortuneJack

Lorem Ipsum is simply dummy text of the printing and typesetting indu...

Icon
Binance

Lorem Ipsum is simply dummy text of the printing and typesetting indu...

Icon
Kraken

Lorem Ipsum is simply dummy text of the printing and typesetting indu...

Top Exchanges
Icon
Binance

4.93

Read Review - Website

Icon
Kraken

4.10

Read Review - Website

Icon
Binance

4.93

Read Review - Website

Top Casinos
Icon
7bitcasino

4.20

Read Review - Website

Icon
FortuneJack

4.55

Read Review - Website

Icon
BitStarz

4.93

Read Review - Website

Trending news

Advertise

Trending news

Top Exchanges
Icon
Binance

4.93

Read Review - Website

Icon
Kraken

4.10

Read Review - Website

Icon
Binance

4.93

Read Review - Website

Icon
Gemini

4.85

Read Review - Website

Icon
Kraken

4.10

Read Review - Website

Top Casinos
Icon
7bitcasino

4.20

Read Review - Website

Icon
FortuneJack

4.55

Read Review - Website

Icon
BitStarz

4.93

Read Review - Website

Icon
FortuneJack

4.55

Read Review - Website

Icon
7bitcasino

4.20

Read Review - Website

Top Sportsbook
Icon
Nitrogen Sports

4.73

Read Review - Website

Icon
SportBet.io

4.60

Read Review - Website

Icon
Nitrogen Sports

4.73

Read Review - Website

Icon
SportBet.io

4.60

Read Review - Website

Icon
1xBit

4.0

Read Review - Website

Author

11 Articles
7255 Followers